Arcturus director granted 15,000 stock options
Arcturus Therapeutics Holdings Inc. reported that director James F. Barlow received a grant of stock options as part of his 2026 board compensation.
Rhea-AI Filing Summary
Arcturus Therapeutics Holdings Inc. reported that director James F. Barlow received a grant of stock options as part of his 2026 board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share.
According to the disclosure, the options vest monthly over a one-year period from the grant date, aligning the director’s compensation with the company’s performance over time. All 15,000 options are shown as held directly following this grant, with an expiration date in 2036.
Insider Trade Summary
Grant/Award: 15,000 shares
Grant/Award
1 txn
Insider
BARLOW JAMES F
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 15,000 contracts (Direct)
Footnotes (1)
- F1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Key Figures
Options granted: 15,000 options
Exercise price: $7.30 per share
Options after transaction: 15,000 options
+2 more
5 metrics
Options granted
15,000 options
Stock option grant to director on June 5, 2026
Exercise price
$7.30 per share
Stock option exercise price for common stock
Options after transaction
15,000 options
Total derivative securities held directly after grant
Option term
Expires June 5, 2036
Expiration date of granted stock options
Vesting period
12 months
Options vest monthly over one year from grant date
Key Terms
Stock option (right to buy), exercise price, vest monthly, Board of Directors
4 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 7.3000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest monthly financial
"Shares underlying the option vest monthly over a one year period"
Board of Directors financial
"annual grant to the Reporting Person as a member of the Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Arcturus Therapeutics (ARCT) report for James F. Barlow?
Arcturus reported that director James F. Barlow received a grant of 15,000 stock options. These options are part of his 2026 annual board compensation and give him the right to buy Arcturus common shares at a set exercise price in the future.
What is the exercise price of James F. Barlow’s new Arcturus (ARCT) stock options?
The granted stock options have an exercise price of $7.30 per share. This means Barlow can purchase Arcturus common stock at $7.30 if he exercises the options, regardless of the market price at the time of exercise, subject to the vesting schedule.
How do the newly granted Arcturus (ARCT) options to James F. Barlow vest?
The 15,000 stock options vest monthly over a one-year period from the grant date. This structure gradually delivers full ownership of the options across twelve months, encouraging ongoing board service and alignment with the company’s performance throughout the year.
When do James F. Barlow’s Arcturus (ARCT) stock options expire?
The granted stock options are scheduled to expire on June 5, 2036. If Barlow does not exercise the options by this expiration date, they will lapse and no longer give him the right to purchase Arcturus common shares at the stated exercise price.
How many Arcturus (ARCT) derivative securities does James F. Barlow hold after this grant?
Following this grant, Barlow is shown holding 15,000 stock options directly. Each option represents the right to acquire one share of Arcturus common stock, subject to vesting and the $7.30 exercise price, providing equity-based compensation tied to future performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
